Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
Exxon Mobil’s XTO Energy Explores Sale of Eagle Ford Shale Assets in South Texas 
NTSB Opens Investigation Into Waymo Robotaxis After School Bus Safety Violations in Texas 
Winter Storm Triggers Widespread Flight Cancellations Across U.S. as Airlines Urge Travelers to Rebook 
Tesla Plans FSD Subscription Price Hikes as Autonomous Capabilities Advance 
Samsung Set to Begin HBM4 Production for Nvidia and AMD 
Goldman Sachs CEO David Solomon’s 2025 Pay Soars to $47 Million After Strong Deal-Making Year 
Shell Plc Downgraded by RBC as Market Headwinds Pressure Valuation 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
U.S. Lawmakers Demand Scrutiny of TikTok-ByteDance Deal Amid National Security Concerns 
Ericsson Plans SEK 25 Billion Shareholder Returns as Margins Improve Despite Flat Network Market 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
SEC Drops Gemini Enforcement Case After Full Repayment to Earn Investors 
Microsoft Restores Microsoft 365 Services After Widespread Outage 
CN Energy Group Inc. Stock Slides After Nasdaq Delisting Notice Over Bid Price Rule 
Delta Air Lines Operates Reduced Flight Schedule as Winter Storm Disrupts U.S. Travel 
NEW YORK, May 12, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of investors who purchased Puma Biotechnology, Inc. ("Puma Biotechnology") (NASDAQ:PBYI) securities between February 29, 2016 and May 4, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra-sa/puma-biotechnology-inc?wire=1. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (i) the Company did not anticipate that the U.S. Food and Drug Administration (“FDA”) would ultimately approve PB272 (“neratinib”) for the treatment of breast cancer; (ii) as such, Puma Biotechnology had overstated the drug’s approval prospects and/or commercial viability; and (iii) as a result, Puma Biotechnology’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Puma Biotechnology you have until July 7, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-sa/puma-biotechnology-inc?wire=1.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
